|
2024
|
P/S
|
Pharmaceutical preparations for the treatment of oncological, neurological, immunological, and ge... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of oncological and immune system related diseases a... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of oncological
and immune system related diseases ... |
|
|
Invention
|
Methods for treating immune refractory lung cancer.
The disclosure features methods for treating... |
|
|
Invention
|
Methods of treating a ras related disease or disorder. The disclosure features methods of treatin... |
|
|
Invention
|
Ras inhibitors. The disclosure features macrocyclic compounds, and pharmaceutical compositions an... |
|
|
Invention
|
Combination therapy for a ras related disease or disorder. The present disclosure relates to comb... |
|
|
Invention
|
Synthesis of ras inhibitors.
The present invention relates to Ras inhibitors and to methods for ... |
|
|
Invention
|
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof... |
|
|
Invention
|
Crystalline forms of a ras inhibitor. The disclosure features crystalline forms of Ras inhibitors... |
|
|
Invention
|
Synthesis of ras inhibitors. The present invention relates to Ras inhibitors and to methods for p... |
|
|
Invention
|
Condensed macrocyclic compounds as ras inhibitors. The disclosure features macrocyclic compounds ... |
|
|
Invention
|
Macrocyclic ras inhibitors. The disclosure features macrocyclic compounds of formula (la) and (lb... |
|
|
Invention
|
Compositions for inducing ras gtp hydrolysis and uses thereof. The present disclosure relates to ... |
|
|
P/S
|
Pharmaceutical preparations. Pharmaceutical research and development; drug discovery services; pr... |
|
|
P/S
|
Pharmaceutical preparations. Pharmaceutical research and development; drug discovery
services; p... |
|
|
Invention
|
Ras inhibitors.
The disclosure features macrocyclic compounds, and pharmaceutical compositions a... |
|
|
Invention
|
Methods and reagents for analyzing protein-protein interfaces.
The present disclosure provides m... |
|
2023
|
P/S
|
Pharmaceutical research and development; drug discovery services; providing information about med... |
|
|
Invention
|
Methods for inhibiting ras.
The disclosure features methods for inhibiting RAS proteins. The dis... |
|
|
Invention
|
Compounds, complexes, and methods for their preparation and of their use. The invention features ... |
|
|
Invention
|
Methods of treating cancer with an mtor inhibitor. The present disclosure relates to methods for ... |
|
|
Invention
|
Covalent ras inhibitors and uses thereof.
The disclosure features compounds, or pharmaceutically... |
|
|
Invention
|
Composition comprising a first ras inhibitor, second ras inhibitor and a shp2 inhibitor for use i... |
|
|
Invention
|
Synthesis of rapamycin analog compounds.
The present disclosure relates to novel methods for pre... |
|
|
Invention
|
Methods for inhibiting ras.
The disclosure features methods for inhibiting RAS proteins, e.g., R... |
|
|
P/S
|
Pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in the treat... |
|
|
Invention
|
Methods of treating cancer. Provided herein are methods of treating a cancer in a patient wherein... |
|
|
Invention
|
Bicyclic compounds as allosteric shp2 inhibitors.
The present disclosure is directed to inhibito... |
|
|
Invention
|
Process for preparing shp2 inhibitors.
Provided herein are methods for preparing an SHP2 inhibit... |
|
|
Invention
|
Macrocyclic ras inhibitors. The disclosure features macrocyclic compounds, and pharmaceutical com... |
|
|
Invention
|
Methods of treating cancer with an mtor inhibitor.
The present disclosure relates to methods for... |
|
|
Invention
|
Sos1 inhibitors and uses thereof. The present disclosure is directed to modulators of SOS1 and th... |
|
|
Invention
|
Pyridine compounds as allosteric shp2 inhibitors.
The present disclosure is directed to inhibito... |
|
|
Invention
|
C26-linked rapamycin analogs as mtor inhibitors. The present disclosure relates to mTOR inhibitor... |
|
|
Invention
|
Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors.
The present disclosure... |
|
|
Invention
|
Identifying new therapeutic agents.
Disclosed herein are methods for identifying novel drug cand... |
|
|
Invention
|
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric sh... |
|
|
Invention
|
Compounds that participate in cooperative binding and uses thereof.
The disclosure features macr... |
|
|
Invention
|
Methods for treating immune refractory lung cancer. The disclosure features methods for treating ... |
|
|
Invention
|
Polycyclic compounds as allosteric shp2 inhibitors.
The present disclosure is directed to inhibi... |
|
|
Invention
|
Shp2 inhibitor compositions and methods for treating cancer.
The present invention is directed t... |
|
2022
|
Invention
|
Pyrazolopyrazine compounds as shp2 inhibitors. Provided herein are compounds and pharmaceutical c... |
|
|
Invention
|
Bicyclic heteroaryl compounds and uses thereof.
The present disclosure is directed to modulators... |
|
|
Invention
|
Ras inhibitors. The invention features macrocyclic compounds, and pharmaceutical compositions and... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of immunological diseases and disorders and oncolog... |
|
|
Invention
|
Use of sos1 inhibitors with ras inhibitors to treat cancers.
The present disclosure relates to c... |
|
|
P/S
|
Pharmaceutical research and development; drug discovery services |
|
2021
|
Invention
|
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors.
The presen... |
|
2015
|
P/S
|
Pharmaceutical preparations for the treatment of oncological diseases and disorders and immuno-on... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of fungal and bacterial diseases and disorders, imm... |
